Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor ...

"Aquablation is like no other transurethral therapy that has come about in the last 100 years," says Ravi Munver, MD. In this video, Ravi Munver, MD, discusses the real-time, ultrasound-guided ...

A 4-gene signature (ATM, RB1, FANCC, ERCC2) correlates with tumor absence post-neoadjuvant chemotherapy in muscle-invasive bladder cancer. The biomarker is more effective at predicting disease ...

UTUC is a rare malignancy, primarily affecting older men, with smoking as a significant risk factor. Nephron-sparing approaches are gaining interest due to complications from nephroureterectomy and ...

Steerable suction catheters and scopes are revolutionizing stone disease surgery, enhancing safety and efficiency. The MONARCH trial and CVAC scope are key innovations in stone removal, allowing ...

Nivolumab addition to standard therapy improved 2-year FFBR to 90.3%, surpassing the historical control rate of 75%. The study cohort showed significant FFBR improvement over the contemporary control ...